⌘K
t
ImmuPharma PLC announced on 03 June 2024 that it realised gross proceeds of c£1.5 million from the sale of its entire holding of c9.9 million shares in Incanthera plc. Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc with an exercise price of 9.5p and an exercise expiry date of 6 September 2024.
| Date | 3 Jun 2024 |
| Time | 10:09:51 |
| Category | Disposals |
| ID | 8529Q |
RNS | 3 June 2024
ImmuPharma PLC
("ImmuPharma" or the "Company")
Realisation of c£1.5 million on sale of shares in Incanthera plc
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc.
Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and exercise expiry date of 6 September 2024.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.